But ELN’s Bap program is partnered (with WYE); I interpreted ghmm’s post to be a call for biotechs with weak finances who have non-partnered programs in phase-3 or beyond.
What we could do is compile two lists: one for companies whose late-stage program(s) are partnered and one for companies whose late-stage program(s) are not partnered.
Market Data 
Markets 
AI
